title: A multicenter, open-label study of an intravenous short-acting β1-adrenergic receptor antagonist landiolol hydrochloride for coronary computed tomography angiography by 16-slice multi-detector computed tomography in Japanese patients with suspected ischemic cardiac disease.
abstract: BACKGROUND
  During coronary computed tomography (CT) angiography (CCTA), β-blockers (β-adrenergic receptor antagonists) have commonly been used to lower heart rate and improve image quality.
  
  
  OBJECTIVE
  The aim of this study was to investigate the image quality-improving effect as well as the heart rate-lowering effect of landiolol hydrochloride (an intravenous short-acting β1-adrenergic receptor antagonist) in CCTA by 16-slice multi-detector CT (MDCT).
  
  
  METHODS
  A total of 39 subjects suspected of having ischemic cardiac disease and requiring CCTA received 0.125 mg/kg of landiolol hydrochloride to study the efficacy and safety of landiolol hydrochloride in a multicenter open-label clinical study. The endpoint was the diagnosable proportion (proportion of subjects whose coronary stenosis was diagnosable).
  
  
  RESULTS
  The diagnosable proportions for the reconstruction images at mid-diastole were 56.0 %. The diagnosable proportions for the optimal reconstruction images were 65.4 %. The mean heart rate-lowering effect was observed soon after administration of landiolol hydrochloride; the peak of the effect was reached in 3-5 min, and the effect wore off in 30 min after completion of administration. The mean heart rate-lowering proportion at that time was -14.46 ± 8.4 %.
  
  
  CONCLUSIONS
  Landiolol hydrochloride was confirmed to reduce heart rate significantly and rapidly after intravenous injection and this suggests that the study drug is a safe and useful agent for improving the image quality of CCTA by 16-slice MDCT.
authors.affiliation: Department of Cardiology, Tokyo Medical University, 6-7-1, Nishi-shinjuku, Shinjuku, Tokyo, 160-0023, Japan, m-hirano@tokyo-med.ac.jp.
authors.forename: Masaharu
authors.initials: M
authors.lastname: Hirano
authors.forename: Akira
authors.initials: A
authors.lastname: Yamashina
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Hara
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ikari
authors.forename: Masahiro
authors.initials: M
authors.lastname: Jinzaki
authors.forename: Misako
authors.initials: M
authors.lastname: Iino
authors.forename: Takuhiro
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Mitsunobu
authors.initials: M
authors.lastname: Tanimoto
authors.forename: Sachio
authors.initials: S
authors.lastname: Kuribayashi
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000368:Aged; D017023:Coronary Angiography / Q000379:methods*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D061330:Multidetector Computed Tomography / Q000379:methods*; D017202:Myocardial Ischemia / Q000175:diagnosis*; D014508:Urea / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000319:Adrenergic beta-Antagonists; D009025:Morpholines; C077049:landiolol; D014508:Urea
references.citation: Chem Pharm Bull (Tokyo). 1992 Jun;40(6):1462-9
references.pmid: 1356643
references.citation: Circ J. 2013;77(1):146-52
references.pmid: 23037522
references.citation: J Am Coll Cardiol. 2008 Dec 16;52(25):2135-44
references.pmid: 19095130
references.citation: JAMA. 2009 Feb 4;301(5):500-7
references.pmid: 19190314
references.citation: Circ J. 2008 Nov;72(11):1814-20
references.pmid: 18827370
references.citation: J Am Coll Cardiol. 2007 Dec 18;50(25):2393-8
references.pmid: 18154964
references.citation: J Am Coll Cardiol. 2004 Sep 15;44(6):1230-7
references.pmid: 15364324
references.citation: Eur Heart J. 2008 Jan;29(2):191-7
references.pmid: 18089704
references.citation: Circulation. 2002 Oct 15;106(16):2051-4
references.pmid: 12379572
references.citation: Circulation. 2005 Oct 11;112(15):2318-23
references.pmid: 16203914
references.citation: J Med Imaging Radiat Oncol. 2012 Feb;56(1):5-17
references.pmid: 22339741
references.citation: Circulation. 2003 Feb 11;107(5):664-6
references.pmid: 12578863
references.citation: AJR Am J Roentgenol. 2005 May;184(5):1413-9
references.pmid: 15855088
references.citation: N Engl J Med. 2008 Nov 27;359(22):2324-36
references.pmid: 19038879
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Apr 1;891-892:7-11
references.pmid: 22418070
references.citation: Eur Heart J. 2004 Jun;25(12):1043-8
references.pmid: 15191775
references.citation: Rofo. 2007 Jun;179(6):581-6
references.pmid: 17492543
references.citation: Circulation. 2008 Jul 29;118(5):586-606
references.pmid: 18586979
references.citation: Clin Drug Investig. 2014 Jan;34(1):53-62
references.pmid: 24174275
references.citation: Adv Ther. 2013 Sep;30(9):803-18
references.pmid: 24062147
references.citation: Eur Radiol. 2009 May;19(5):1114-23
references.pmid: 19089430
references.citation: Int J Cardiovasc Imaging. 2013 Jun;29 Suppl 1:7-20
references.pmid: 23784548
references.citation: J Am Coll Cardiol. 2004 Jun 16;43(12):2265-70
references.pmid: 15193691
references.citation: Circulation. 2010 Jun 8;121(22):2509-43
references.pmid: 20479158
references.citation: JAMA. 2005 May 25;293(20):2471-8
references.pmid: 15914747